Andrew H. Miller

Andrew H. Miller

Auto-generated profile, based on publicly available information

Andrew H. Miller

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2015 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
AMAndrew H. Miller
Andrew H. Miller
CRCharles L. Raison
Charles L. Raison

1 May 2009 in Biological Psychiatry
Verified
Journal Article
Closed access
AMAndrew H. Miller
Andrew H. Miller
VMVladimir Maletic
Vladimir Maletic
CRCharles L. Raison
Charles L. Raison

1 January 2006 in Trends in Immunology
Verified
Journal Article
Closed access
CRCharles L. Raison
Charles L. Raison
LCLucile Capuron
Lucile Capuron
AMAndrew H. Miller
Andrew H. Miller

1 January 2013 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
CRCharles L. Raison
Charles L. Raison
RRRobin E. Rutherford
Robin E. Rutherford
BWBobbi J. Woolwine
Bobbi J. Woolwine
CSChen Shuo
Chen Shuo
PSPamela Schettler
Pamela Schettler
AMAndrew H. Miller
Andrew H. Miller
Despite advances in the treatment of major depression, one-third of depressed patients fail to respond to conventional antidepressant medication.1 One pathophysiologic mechanism hypothesized to contribute to treatment resistance in depression is inflammation. A number of inflammatory biomarkers (including inflammatory cytokines, acute phase proteins, chemokines, and adhesion molecules) have been found to be reliably elevated in depressed patients and have been associated with a decreased likelihood of response to conventional antidepressants.2-4 Moreover, factors linked to a poor antidepressant treatment response, including early life stress, anxiety disorders, and neuroticism, have been associated with increased inflammation.5-11 Data also indicate that inflammatory cytokines can sabotage and circumvent the mechanisms of action of conventional antidepressant medications.2 For example, inflammatory cytokines can increase the expression and activity of monoamine transporters, the primary antidepressant target for monoamine reuptake inhibition.12,13 In addition, inflammatory cytokines can reduce the concentration of monoamine precursors through the activation of enzymes such as indoleamine 2,3-dioxygenase, which breaks down tryptophan, the primary amino acid precursor for serotonin, into kynurenine.14 Inflammation can also reduce the availability of the enzyme cofactor, tetrahydrobiopterin, which is essential for activities of tryptophan hydroxylase and tyrosine hydroxylase, which are rate-limiting enzymes for synthesis of serotonin, norepinephrine, and dopamine.15,16 Inflammatory cytokines have also been shown to inhibit neurogenesis through the activation of nuclear factor κB.17 Neurogenesis is an important component of the salutary effects of conventional antidepressants in several depressive-like behaviors in animal models of depression, including anhedonia.18-20 Finally, inflammatory cytokines can reduce the number of glutamate transporters that are expressed and increase the amount of glutamate that is released from astrocytes, thereby activating pathophysiologic mechanisms (eg, glutamate excitotoxicity) that are not primary targets of conventional antidepressant medications.2,15,21,22

1 May 2011 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
LCLucile Capuron
Lucile Capuron
AMAndrew H. Miller
Andrew H. Miller

1 September 2003 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
CRCharles L. Raison
Charles L. Raison
AMAndrew H. Miller
Andrew H. Miller